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We have earlier shown that microglia, the immune cells of
the CNS, release microparticles from cell plasma mem-
brane after ATP stimulation. These vesicles contain and
release IL-1b, a crucial cytokine in CNS inﬂammatory
events. In this study, we show that microparticles are
also released by astrocytes and we get insights into the
mechanism of their shedding. We show that, on activation
of the ATP receptor P2X7, microparticle shedding is asso-
ciated with rapid activation of acid sphingomyelinase,
which moves to plasma membrane outer leaﬂet. ATP-
induced shedding and IL-1b release are markedly reduced
by the inhibition of acid sphingomyelinase, and comple-
tely blocked in glial cultures from acid sphingomyelinase
knockout mice. We also show that p38 MAPK cascade is
relevant for the whole process, as speciﬁc kinase inhibi-
tors strongly reduce acid sphingomyelinase activation,
microparticle shedding and IL-1b release. Our results
represent the ﬁrst demonstration that activation of acid
sphingomyelinase is necessary and sufﬁcient for micro-
particle release from glial cells and deﬁne key molecular
effectors of microparticle formation and IL-1b release,
thus, opening new strategies for the treatment of neuroin-
ﬂammatory diseases.
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Introduction
Cells communicate and exchange information by different
secreting mechanisms. Among these, extracellular vesicles
(exosomes and plasma membrane (PM)-derived microparti-
cles, MPs) are gaining increasing attention as efﬁcient vehi-
cles for the release of signalling molecules. Exosomes are
secreted as a result of multivesicular bodies (MVB) fusion
with the PM, represent a population of vesicles homogenous
in size and shape (40–80nm). PM-derived MPs represent
instead a heterogeneous population of vesicles larger than
exosomes (100nm–1mm), which bud directly from the PM of
healthy cells and contain cytoskeleton and ER elements
(Ratajczak et al, 2006). MPs have high levels of phosphati-
dylserine (PS) exposed to the outer membrane (MacKenzie
et al, 2001), whereas exosomes have lower PS exposed to the
outer membrane leaﬂet, depending on cell type and stimuli,
but over express tetraspanin superfamily of proteins, includ-
ing CD63 (Heijnen et al, 1999; The ´ry et al, 2001; Morelli et al,
2004; Simpson et al, 2008). Both exosomes and MPs control
fundamental cellular responses, such as intercellular signal-
ling and immune reactions (Ratajczak et al, 2006; Simpson
et al, 2008). Release of exosomes has received only limited
attention in the CNS (Potolicchio et al, 2005; Faure ´ et al, 2006;
Schiera et al, 2007; Taylor et al, 2007), where these organelles
might mediate cell-to-cell transfer of proteins, lipid compo-
nents or mRNAs, as already demonstrated outside the CNS
(Smalheiser, 2007). So far, regarding MP release in the CNS,
there is only one study (Bianco et al, 2005) showing that
microglia release MPs on ATP stimulation. Microglial MPs
store and release the inﬂammatory cytokine IL-1b (Bianco
et al, 2005), a leaderless protein that is not liberated through
the default Golgi secreting pathway. Pro-IL-1b is present in
MPs 10min after microglia exposure to ATP, and it is then
released into the medium (Bianco et al, 2005). Besides MPs
(MacKenzie et al, 2001; Bianco et al, 2005), different path-
ways of secretion mediate IL-1b release in distinct cell types.
Among these, release of exosomes (Qu et al, 2007), exocytose
of secretory lysosomes (Andrei et al, 1999), and direct efﬂux
through PM transporters (Marty et al, 2005). In microglia, MP
shedding is rapidly induced by the activation of the iono-
tropic ATP receptor P2X7 (P2X7R). Activation of the receptor
can occur at the site of lesion by ATP leaking from degenerat-
ing cells (Ferrari et al, 1997) or, distantly from the lesion,
through propagation of ATP-mediated Ca
2þ wave among
astrocytes, a process that has a function in pathological
signalling events (Nedergaard et al, 2003). The P2X7Ri sa
ligand-gated ATP receptor, which, besides acting as a channel
and pore, is known to be coupled to several downstream
effectors and protein kinases (Duan and Neary, 2006). P2X7R-
mediated MP shedding is preceded by exposure of PS at the
cell surface, loss of PM asymmetry and formation of
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1043membrane protrusions, described in the literature as blebs.
Intracellular signalling events required for MP release involve
multiple pathways initiated by agonist occupancy of the
P2X7R, including activation of ROCK and p38 MAP kinase
(p38 MAPK) (Morelli et al, 2003; Verhoef et al, 2003),
similarly to apoptotic blebbing (Coleman et al, 2001).
However, P2X7R-induced morphological changes leading to
MP release are reversible and not linked to apoptotic cell
death (MacKenzie et al, 2001; Verhoef et al, 2003). How
signalling by P2X7R leads to membrane blebbing is not
known. In particular, nothing is known about P2X7R-induced
alterations of the biophysical properties of the PM, which
together with actin-cytoskeleton reorganisation are a prere-
quisite for membrane blebbing and vesiculation at the surface
of healthy cells. Blebbing and vesiculation in response to
apoptotic stimuli, during the ﬁnal stages of cell death, depend
on breakdown of sphingomyelin (SM), a phospholipid abun-
dant in the outer leaﬂet of the PM. SM has a high afﬁnity for
cholesterol and both lipids are major determinants of mem-
brane ﬂuidity and structural integrity of the PM (Simons and
Ikonen, 1997). SM hydrolysis, catalysed by the enzyme
family of sphingomyelinases (SMases), results in increased
efﬂux of cholesterol and increased membrane ﬂuidity (Slotte
et al, 1989; Neufeld et al, 1996), thus inducing membrane
destabilisation and facilitating membrane blebbing and MP
shedding (Van Blitterswijk et al, 1982; Chang et al, 1993;
Tepper et al, 2000). Therefore, we investigated the role of
SMases in P2X7R-triggered blebbing and found that receptor
stimulation leads to the activation of a speciﬁc SMase, acid
SMase (A-SMase) with rapid SM hydrolysis and MP forma-
tion. We also showed the obligatory role of A-SMase in the
short term, non-apoptotic process of MP production and
showed that A-SMase acts as a P2X7R effector, downstream
of p38 phosphorylation, thus, deﬁning the role of p38 activa-
tion in membrane blebbing.
Results
P2X7-dependent MP shedding from astrocytes
We have earlier shown that stimulation of P2X7R by ATP or
the selective agonist Benzoyl-ATP (BzATP) induces MP shed-
ding from microglia cell surface (Bianco et al, 2005). In this
study, we show that MP shedding occurs also in astrocytes.
To study the dynamics of MP formation, we brieﬂy labelled
the lipid bilayers of primary cortical astrocytes or glial cell
lines with the ﬂuorescent styryl dye FM1–43 or with the
ﬂuorophore-conjugated phosphocholine compound NBD
C6-HPC and observed the cells by time-lapse ﬂuorescence
video microscopy. By this approach, we observed not only
the formation (Figure 1A) but also the shedding from the PM
of variably sized vesicles on 100mM BzATP exposure
(Figure 1B and C; Supplementary Movie). To quantify the
shedding process, supernatant of glial cells exposed to BzATP
for 20min were pelleted at 10000g, to separate MPs as pellet
(Heijnen et al, 1999). Fluorescence of pelleted MPs was then
quantiﬁed by spectrophotometric analysis (Supplementary
Figure 1; see also Figure 2). Several perturbants were tested
for their effects on MP shedding, including the P2X7 antago-
nists Brilliant Blue G (100nM) and KN-62 (10mM), the P2X2,4
antagonist TNP-ATP (3nM), the Rho-effector kinase inhibitor
Y-27632 dihydrochloride (100mM) and the actin polymerisa-
tion inhibitor cytochalasin D (2mg/ml), as well as perturbants
of Ca
2þ homeostasis, such as the Ca
2þ chelators EDTA
(500mM) and BAPTA (30mM) and the Ca
2þ ionophore iono-
mycin (10mM). Phorbol ester PMA (1mM) was also used as
positive control for the shedding process. The results of this
analysis indicated that BzATP-induced MP shedding in astro-
cytes requires both P2X7R activation and cytoskeleton reor-
ganisation, and it is dependent on both extracellular and
cytoplasmic Ca
2þ (Figure 1D and E).
Time course analysis of MP release in the medium indi-
cated a gradual increase that is already signiﬁcant 5min after
P2X7R stimulation reaching a plateau after 20min
(Figure 1F). Consistent with these data, time-lapse video
microscopy indicated that MP shedding starts in about 1
and 2min after P2X7R activation and persists for several
minutes in the continuous presence of the receptor agonist
(not shown).
Biochemical and morphological characterisation
of distinct types of vesicles released from glial cells
To deﬁne the nature of ﬂuorescent MPs shed from the PM
distinguishing them from exosomes, we analysed the size and
molecular features of both extracellular vesicle populations,
MPs and exosomes, released from glial cells under these
conditions. To this aim, the supernatants of glial cells were
subjected to differential centrifugation (Supplementary data)
followed by negative staining electron microscopy, ﬂuores-
cence microscopy and western blotting analysis. By this
combined approach, we could analyse also small vesicles
pinching off from the PM and exosomes that could not be
sized at video microscopy resolution. Vesicles of distinct sizes
were detected by negative staining electron microscopy in the
P2 (1200g), P3 (10000g) and P4 (110000g) pellets. The P4
pellet consisted of cup-shaped vesicles in the range of
30–80nm, corresponding to exosome size, whereas the P3
and P2 pellets contained relatively larger vesicles, characterised
by a mean diameter of 155±6 and 426±51nm, respectively
(Figure 2A). Similar results were obtained with N9 microglia
(Supplementary Figure 2A). Given that PM-derived MPs,
differently from exosomes, present high levels of PS exposed
to the outer membrane, we used this information to further
characterise P2–P4 populations. Vesicles present in P2, P3
and P4 pellets were imaged by ﬂuorescence microscopy after
incubation with NBD C6-HPC (3mM), to stain vesicle mem-
brane, or with FITC-annexin V (4.2mg/ml), indicative of the
presence of PS on the outer membrane. We found that PS is
exposed on the surface of P2 and P3 but not P4 vesicles, thus,
suggesting that P2 and P3 MPs mainly derive from PM
blebbing. Although optical resolution is approximately
200nm, we excluded that the lack of annexin V signal in P4
vesicles was due to resolution limits, as P4 vesicles could be
visualised, although not sized, when treated with NBD
(Figure 2B; Supplementary Figure 2B). Indeed quantitative
analysis of annexin V binding to vesicles by ﬂow cytometry
analysis (FACS) indicated the presence of PS on the outer
membrane in 70% P2, 36% P3 but only 5% of P4 vesicles
(Figure 2C). P2–P4 vesicles were also analysed by western
blotting (Supplementary data; Figure 2D; Supplementary
Figure 2D), and/or ﬂuorescence microscopy (Figure 2B) for
some PM and exosome markers, to further characterise the
nature of P2–P4 vesicles. Typical exosome markers, such as
CD63 and heat shock protein HSP70 were clearly found in the
P4 pellet, identifying P4 vesicles as exosomes. Few CD63
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although not detectable by western blotting (Figure 2D),
probably due to the lower sensitivity of the antibody in
immunoblotting than in immunocytochemistry. Conversely,
P2 and P3 vesicles were positive for different PM markers
including the cannabinoid receptor CB1, the glutamate trans-
porter GLAST and Na
þ/K
þ ATPase (Figure 2B and D;
Supplementary Figure 2D). However, only CB1, among PM
markers, was exclusively detected in P2 and P3 MPs
(Supplementary Figure 2D). Both Na
þ/K
þ ATPase and
GLAST were indeed detectable also in the P4 exosome frac-
tion (Figure 2B and D). This ﬁnding is consistent with the
presence in exosomes of speciﬁc cell-surface proteins includ-
ing integrins and cell adhesion molecules (Smalheiser, 2007).
We then evaluated which vesicle populations mediate
IL-1b in astrocytes. Notably, western blotting of P2–P4 frac-
tions for IL-1b indicated that the bulk of the pro-cytokine is
present in PM-derived MPs pelleted in the P2 fraction. This
analysis was carried out in both astrocytes (Figure 2D) and
N9 microglial cells (Supplementary Figure 2D) exposed to
BzATP for 15min, a time point when about 80% of the
released cytokine is detected inside MPs having PS on the
membrane (Bianco et al, 2005). Overall, these results clearly
indicate that PM-derived MPs and not exosomes mainly
contributes to IL-1b release from glial cells.
A-SMase is enriched in glia-derived MPs
SMases catalyse the hydrolysis of SM into ceramide and
phosphorylcholine thus controlling PM ﬂuidity. Three forms
of SMases with an optimal acidic, neutral, or alkaline pH
have been described (Gulbins et al, 2000). Among SMases,
A-SMase is activated rapidly on stimulation of various recep-
tors, being recruited to the PM to mediate receptor-dependent
signalling (Grassme ´ et al, 2001; Gulbins, 2003; Marchesini
and Hannun, 2004). To investigate whether A-SMase may be
involved in the P2X7R-induced budding and release of MPs,
we evaluated by western blotting the expression of A-SMase
in MPs released from glial cells, isolated either by differential
centrifugation (Figure 2D; Supplementary Figure 2D) or by
binding to annexin V coated beads (Figure 2E), a method
that allows selective enrichment of MPs exposing PS
(Supplementary data). A signiﬁcant enrichment of A-SMase
in the PM-derived MPs was observed as compared with glial
lysates.
A-SMase mediates P2X7R-dependent MP shedding
To investigate the speciﬁc involvement of A-SMase in MP
production, we directly measured A-SMase activity in micro-
glia exposed for different time points to BzATP. Kinetic
analysis of A-SMase activity revealed a peak of enzyme
activity at 2min after agonist addition (Figure 3A), indicating
Figure 1 P2X7-dependent MP shedding from glial cells. (A–C) Fluorescence images of FM1-43-labelled microglial N9 cells during 100mM
BzATP exposure (A, bar, 5mm). Frames were taken at the indicated times after BzATPaddition. BzATP treatment induces the formation of FM1-
43-labelled vesicles along microglia philopodia (arrows). Fluorescence images of cortical astrocytes labelled with FM1-43 (B, bar, 1mm) or
NBD-labelled glioma cells (C, bar, 5mm), showing the MP shedding from PM on BzATP exposure (see also Supplementary Movie). (D, E) The
histograms show the spectrophotometric analysis of large ﬂuorescent MPs pelletted at 10000g from supernatants of primary astrocytes (D) or
N9 microglial cells (E) pre-labelled with FM1–43 and exposed to 100mM BzATP for 20min at 371C. A signiﬁcant reduction is observed in the
amount of MPs released by cells exposed to BzATP after treatment with P2X7R antagonists (BBG, KN-62, TNP), the Rho-effector kinase
inhibitor Y-27632 (Y27), the actin polymerisation inhibitor cytochalasin D (cytD) or the Ca
2þ chelators BAPTA and EDTA. Besides BzATP,
ionomycin (IONO) and PMA were also able to stimulate MP release (n¼4, Po0.01, ANOVA analysis, Dunnet’s method).
(F) Spectrophotometric analysis of MPs pelleted at 10000g from supernatants collected from FM1-43-labelled cortical astrocytes at different
time points after BzATP stimulation, showing the kinetic of vesicle accumulation into the extracellular medium.
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Although A-SMase activation period is shorter than that of
MP release (Figure 1F), it is plausible that increased gener-
ated ceramide has long-lasting effects on membrane ﬂuidity
required for P2X7-dependent blebbing. Activation of A-SMase
by P2X7R was accompanied by enzyme translocation to the
PM outer leaﬂet, as shown by the increased A-SMase staining
detected by FACS in intact cells (Figure 3B). A-SMase trans-
location to the PM outer leaﬂet on P2X7R activation was
conﬁrmed by biotynilation and western blotting experiments
that revealed surface expression of the enzyme in cultured
astrocytes during BzATP exposure (Figure 3C). Finally,
A-SMase translocation was also suggested by movement of
the enzyme from the exosomal fraction (P4) to PM-derived
fractions, P2 and P3, on BzATP stimulation of microglial cells
(Figure 3D). Interestingly, FACS analysis of intact P2, P3 and
P4 vesicles for A-SMase revealed immunoreactivity for the
enzyme in P2 and P3 but not in P4 pellet (Figure 3E). P4
vesicles were negative for outer A-SMase also under non-
stimulating conditions (not shown), when these vesicles have
highest luminal concentration of the enzyme (Figure 3D).
These results, together with the presence of A-SMase in P4
fraction (Figures 2D and 3D), indicated both association of
the enzyme to the outer leaﬂet of MPs and luminal localisa-
tion of A-SMase in exosomes. Furthermore, FACS experiments
on intact vesicles doubled labelled with A-SMase and annexin
V revealed that A-SMase immunoreactivity represented
87±5% of total MPs exposing PS (not shown), indicating
that the presence of the enzyme on MPs is instrumental for
vesicle budding from PM.
To investigate whether A-SMase activity could facilitate
formation of membrane protrusions and membrane vesicula-
tion, microglia were exposed to exogenous recombinant
SMase (r-SMase), which has an acid pH optima and displays
little activity at neutral pH. Spectrophotometric quantiﬁcation
of the amount of MPs shed on exposure to r-SMase revealed
that the enzyme is by itself sufﬁcient to stimulate MP shed-
ding. Similar results were obtained when astrocytes were
exposed to bacterial SMase (b-SMase), thus indicating that
ceramide generation is the key player in the shedding process
Figure 2 Morphological and biochemical characterisation of MPs released by cortical astrocytes. (A) Negative staining electron microscopy of
P2 (bar, 300nm), P3 (bar, 300nm) and P4 (100nm) vesicles pelleted from supernatant of astrocyte exposed to 100mM BzATP for 20min was
carried out as described in Supplementary Figure 2. Number of analysed vesicles from three different preparations: n¼50, P2; n¼161, P3;
n¼184, P4. (B) Fluorescence images of P2, P3 and P4 vesicles stained by NBD, annexin V, the exosome marker CD63 and Na
þ/K
þ ATPase or
GLAST, as PM markers. Bar, 5mm. (C) FACS of astrocyte-derived P2, P3 and P4 vesicles labelled by annexin V-PE and NBD. (D) Western
blotting of P2, P3 and P4 lysates obtained from medium conditioned for 30min by 100mM BzATP-treated astrocytes for IL-1b, A-SMase,
membrane (GLAST) and exosome (CD63, HSP70) markers. Vesicle were loaded as described in Supplementary data. HSP70 staining is below
ECL detectability in P4 vesicles 30min after BzATP stimulation, but become clearly detectable in P4 vesicles on longer conditioning (24h). For
IL-1b blotting, vesicle fractions were obtained from supernatant of astrocytes exposed to BzATP for 15min. (E) Immunoblot analysis of
A-SMase and Na
þ/K
þ ATPase in glial lysates and PM-derived MPs isolated by annexin V-coated beads (Supplementary data).
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downstream of P2X7R, cell exposure to r-SMase also triggered
MP shedding either in a P2X7-deﬁcient microglial cell clone
(Figure 3F) or when P2X7R activation was prevented by
speciﬁc antagonists, such as KN-62 (Figure 3G).
To directly prove the involvement of endogenous A-SMase
in MP shedding, we then evaluated the effects of the A-SMase
inhibitor imipramine (10mM) on the amount of MPs. A clear
inhibition of MP shedding from astrocytes (Figure 4C) and
microglia (Supplementary Figure 3A) was detected with
imipramine. No inhibitory effect was instead observed in
cultures treated with inhibitors of neutral SMase (N-SMase)
such as manumicyn (1mM) or GW4869 (5mM), which has
been recently described to control exosome release (Trajkovic
et al, 2008). Given that imipramine is not very speciﬁc for
A-SMase and can interfere with other enzyme activities, the
role of A-SMase in vesicle shedding was also proven in
astrocyte cultures established from A-SMase heterozygous or
knockout (KO) mice (Figure 4A and B). MP shedding was
completely abolished in astrocytes from A-SMase KO and
signiﬁcantly reduced in astrocytes from heterozygous mice as
compared with wild-type cultures (Figure 4D). Addition of r- or
b-SMase efﬁciently induced MP shedding in KO astrocytes, as
well as in heterozygous cultures, further indicating that SMase
activity is sufﬁcient to induce release of PM-derived MPs.
A-SMase activity mediates P2X7-dependent IL-1b
release
We then examined whether pharmacological inhibition of
A-SMase activity or genetic deﬁciency of A-SMase could affect
IL-1b release from either microglia or cortical astrocytes,
which also release the cytokine on BzATP stimulation
(Bianco et al, unpublished data). ELISA of IL-1b levels in
the supernatants from cells pre-treated with imipramine
indicated a strong reduction of cytokine release (Figure 4E;
Supplementary Figure 3B). Furthermore, IL-1b release was
completely abolished or strongly reduced in astrocyte cul-
tures prepared from A-SMase KO or heterozygous mice,
respectively (Figure 4F). Although an IL-1b expression
reduction of about 50% was detected by optical density
analysis in astrocyte homogenates from A-SMase KO cultures
as compared with controls (Figure 4B for an example of
western blotting), exposure to r- or b-SMases partially
restored BzATP-induced IL-1b release (Figure 4F), thus,
Figure 3 A-SMase is activated downstream of P2X7R stimulation. (A) Time course of A-SMase activation by 100mM BzATP versus not
stimulated cells as control, determined in cell lysates by measuring hydrolysis of sphingomyelin to phosphorylcholine at pH 5.5. Values are
expressed as fold increases over basal A-SMase activity (1.12±0.3nmol/mgh
 1) conventionally indicated as 1 (n¼3). (B) A-SMase
translocation onto the PM on P2X7R stimulation as determined by FACS analysis of intact N9 microglial cells. The relative ﬂuorescence
intensity (RFI) was calculated as ratio of sample mean ﬂuorescence over negative control mean ﬂuorescence. The RFI values reported in the
panels are the mean±s.e.m. measured in the three experiments. The results shown are from one out of three experiments. (C) Surface
exposure of A-SMase on P2X7R stimulation, as detected by western blotting of biotinylated PM proteins with the A-SMase antibody.
(D) Western blot analysis for A-SMase of P2, P3 and P4 vesicles accumulated in the supernatant of microglia cells under basal conditions
or on stimulation with 100mM BzATP for 30min. (E) FACS analysis of intact P2, P3 and P4 vesicles for surface A-SMase, showing most of
association of the enzyme to the outer leaﬂet of P2 and P3 MPs. (F) Spectrophotometric analysis of ﬂuorescent MPs present in total
supernatants collected from either FM1-43-labelled N9 microglial cells (black bars) or FM1-43-labelled N9 microglial clone, not expressing the
P2X7R (white bars), 20min after A-SMase (2U/ml) or BzATP (100mM) addition. (G) Quantitative analysis of FM1-43-labelled vesicles in the
total supernatants of microglial cells exposed to exogenous A-SMase in the presence/absence of the P2X7R antagonist KN-62 or the ATP
degrading enzyme apyrase.
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speciﬁc effects in A-SMase KO astrocytes. These data clearly
indicate that A-SMase activity has an important function in
IL-1b release by controlling P2X7-dependent vesiculation.
Src kinase-dependent phosphorylation of p38 MAPK
is involved in P2X7-induced A-SMase activation
P2X7R is a ligand-gated ion channel, which induces the
opening of large membrane pores, recently identiﬁed as
pannexin-1 hemichannels (Pelegrin and Surprenant, 2006,
2007; Locovei et al, 2007). Independently of the molecular
entity of the pore, several pieces of evidence indicate that
P2X7-induced pore formation requires activation of p38
MAPK cascade (Suzuki et al, 2004). We observed by western
blotting that a brief BzATP exposure induces a prompt p38
MAPK phosphorylation in microglia (not shown) and cortical
astrocytes (Figure 5A). p38 phosphorylation peaked 2–5min
after receptor stimulation and then slowly declined, being
still above control levels 30min after agonist addition.
BzATP-induced p38 phosphorylation was prevented by the
p38 speciﬁc inhibitor SB-203580 (400nM, Figure 5B), by the
kinase inhibitor genistein (50mM, Figure 5B), and the src-
kinase inhibitor PP2 (10mM, not shown), indicating that p38
phosphorylation is mediated by an src-kinase family member,
as suggested previously (Suzuki et al, 2004). BzATP-induced
p38 activation was independent of the channel activity of the
receptor, as it efﬁciently occurred also in the absence of
extracellular Na
þ and Ca
2þ and in the presence of high
extracellular K
þ ions (Figure 5B). Consistent with the
involvement of an src-family protein kinase in P2X7-mediated
p38 activation, exposure of astrocytes to BzATP in the
presence of either PP2, genistein as well as SB203580 failed
to induce pore opening, as assayed by YO-PRO-1 uptake
(Figure 5C).
To evaluate whether P2X7-mediated p38 phosphorylation
and large pore formation could be relevant for A-SMase
activation and vesiculation, A-SMase activity and MP shed-
ding were analysed in microglial cells pre-treated with
inhibitors of the p38 cascade. Inhibition of p38 strongly
reduced A-SMase activity in microglia (Figure 5D) as well
as the enzyme translocation to the PM (Figure 5E and F),
thus indicating that A-SMase activation and membrane
Figure 4 Endogenous A-SMase mediates P2X7-induced vesicle shedding and IL-1b release. (A) Confocal images of cultured astrocytes from wt
and A-SMase KO mice, stained for A-SMase (red) and falloidin (green) to show the speciﬁcity of A-SMase Ab. (B) Western blotting for A-SMase,
IL-1b and GFAP carried out on wild type and A-SMase KO astrocyte lysates primed with LPS. (C) Quantitative analysis of 10000g pelleted MPs
from FM1-43-labelled astrocytes pre-treated or not with the A-SMase inhibitor imipramine or the neutral SMase (N-SMase) inhibitors
manumycin or GW4869, and then exposed to 100mM BzATP for 20min (n of experimental sessions¼2, Po0.01, ANOVA analysis, Scheffe’s
method). (D) Spectrophotometric analysis of MPs present in the total supernatants collected from FM1-43-labelled astrocytes from A-SMase-
wild type (þ/þ), heterozygous (þ/ )o rK O(  / ) mice. Astrocytes were exposed to 100mM BzATP, recombinant (r-SMase) or bacterial
(b-SMase) SMase, or a combination of BzATP and r-SMases/b-SMases (n of experimental sessions¼2; Po0.01, ANOVA analysis, Tukey’s
method). (E) ELISA evaluation of IL-1b levels in the supernatant of LPS-primed astrocytes exposed to 100mM BzATP for 30min, in the
presence/absence of A-SMase inhibitors. Thirty minutes after BzATP addition, IL-1b is clearly detectable in vesicle-free supernatant fraction.
n¼3; Po0.01, ANOVA analysis, Tukey’s method. (F) ELISA for IL-1b on supernatant collected from BzATP-stimulated cortical astrocytes from
A-SMase wild type (þ/þ), heterozygous (þ/ )o rK O(  / ) animals. BzATP-induced IL-1b release is completely blocked in KO cultures and
partially rescued by addition of either r-SMase or b-SMase (n of experimental sessions¼2, Po0.01, ANOVA analysis, Tukey’s method). Both
r-SMase and b-SMase failed to induce IL-1b release in the absence of BzATP stimulation, conﬁrming requirement of P2X7R activation for the
cytokine processing and release (Sanz and Di Virgilio, 2000).
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phorylation. As a consequence, MP shedding from either
microglia (not shown) or cortical astrocytes (Figure 5G)
pre-exposed to either SB-203580, genistein or PP2 was
strongly reduced. No signiﬁcant attenuation of MP shedding
was induced by the ERK1/2 inhibitor U126 (10mM)
(Figure 5G). Moreover, IL-1b detection by ELISA on super-
natants of astrocytes treated with SB-203580, PP2 or genistein
revealed a strong reduction of cytokine release, thus indicat-
ing a clear involvement of p38 cascade in the process of
cytokine release (Figure 5H).
We then investigated whether p38-dependent activation of
A-SMase could be involved in P2X7-induced pore formation.
An efﬁcient YO-PRO-1 uptake was observed in microglial pre-
treated with imipramine (Figure 6A; Supplementary data),
indicating that A-SMase inhibition does not alter the capabil-
ity of P2X7R to open large membrane pores. Accordingly, no
signiﬁcant differences in YO-PRO-1 uptake kinetics were
detected in astrocytes from A-SMase KO and heterozygous
mice as compared with astrocytes from wild-type animals
(Figure 6B). These data suggest that MP shedding and pore
opening are two P2X7-dependent processes that are regulated
by two parallel pathways, downstream of p38 phosphoryla-
tion (Figure 7).
Discussion
A-SMase is required for MP shedding in glial cells
In this study, we show that P2X7-dependent shedding of PM-
derived MPs is not restricted to microglia in the brain, as also
astrocytes can shed MPs containing IL-1b. Glia-derived MPs
present in the CNS, besides containing leaderless molecules
relevant for neuroinﬂammation, could also represent a gen-
eral mechanism used for signalling to other cells, such as
neurons, through the intercellular transfer of protein/lipid
components. All these reasons prompted us to further inves-
tigate the molecular mechanisms involved in glial MP forma-
tion and shedding.
Figure 5 Src kinase-dependent phosphorylation of p38 MAPK mediates P2X7-induced A-SMase activity. (A) Time course of p38 MAPK
phosphorylation in astrocytes exposed to 100mM BzATP for 2, 15 and 30min. Right panel shows the quantitative analysis of P-p38
immunoreactivity normalised to ribophorin from three independent experiments. (B) Western blot analysis of cortical astrocytes exposed
for 2min to 100mM BzATP in the presence/absence of the p38 MAPK inhibitor SB-203580 (400nM) or the kinase inhibitor genistein (10mM).
Astrocytes were also exposed to BzATP in the absence of extracellular Na
þ and Ca
2þ and high extracellular K
þ ions to inhibit ions inﬂux.
Right panel shows the quantitative analysis of P-p38 immunoreactivity normalised to the astrocyte marker ribophorin. (C) Time course
analysis of Yo-PRO-1 uptake in astrocytes exposed to 100mM BzATP in the absence or in the presence of the inhibitors of p38 MAPK
phosphorylation pathway. Yo-PRO-1 uptake is sensitive to the inhibition p38 MAPK phosphorylation (n¼3; Po0.01, ANOVA analysis,
Dunnett’s method). (D) A-SMase activity triggered by 100mM BzATP treatment in the presence/absence of the p38 MAPK inhibitor SB-203580
(400nM) or the src-kinase inhibitor PP2 (10mM) (n¼3; asterisks: Po0.01 versus control) normalised as described in Figure 3. (E, F) A-SMase
exposure onto the PM induced by 100mM BzATP treatment in the presence (E)/absence (F) of the p38 MAPK inhibitor SB-203580 (400nM)
measured by FACS in intact N9 microglial cells. The relative ﬂuorescence intensity (RFI) was calculated versus negative controls. The results
shown are from one experiment representative of three reproducible ones. The RFI values are determined as described in Figure 3.
(G) Quantitative analysis of MPs pelleted at 10000g from the supernatants of FM1-43-labelled astrocytes exposed to 100mM BzATP in the
presence/absence of inhibitors of p38 MAPK phosphorylation pathway. FM1-43-labelled MPs pelleted at 10000g from the supernatants of
astrocytes exposed to BzATP in the presence/absence of inhibitors of p38 MAPK phosphorylation pathway. (H) ELISA for IL-1b on supernatant
conditioned for 30min by 100mM BzATP-stimulated astrocytes in the presence/absence of inhibitors of p38 MAPK phosphorylation pathway.
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triggered by P2X7R stimulation that activates and recruits
A-SMase. Of note, these results are consistent with previous
evidence supporting a role of SMases in the budding of
vesicles from microspheres (Nurminen et al, 2002), budding
of exosomes into MVB (Trajkovic et al, 2008) and in apoptotic
blebbing (Tepper et al, 2000), and with recent observation
that P2X7R activation induces ceramide accumulation
(Lepine et al, 2006). Both apoptotic blebbing and budding
of exosomes into MVB result, however, from the activation of
N- rather than A-SMase. The role of N-SMase in exosome
release from oligodendrocytes (Trajkovic et al, 2008), to-
gether with the involvement of A-SMase in MP formation
from glial cells (this study), indicate that different members
of the SMase family speciﬁcally control the release of distinct
populations of extracellular vesicles in the CNS.
Here, we provide evidence of a causal relationship be-
tween A-SMase activity and MP shedding and show that
A-SMase is both sufﬁcient and necessary for the shedding
process in glial cells. First, A-SMase becomes promptly
activated and translocated onto the PM on P2X7R stimulation,
and the time course of its activation is consistent with that of
MP shedding. Second, addition of exogenous r-SMase
efﬁciently stimulates MP shedding, also in P2X7-deﬁcient
microglia or in cells where the receptor activation is pharma-
cologically prevented. Finally, evidence obtained in cultures
from KO mice indicates that absence of A-SMase completely
abolishes MP release, which can be, however, rescued by
Figure 6 A-SMase activity does not control pore opening. (A) Time course analysis of Yo-PRO-1 uptake in astrocytes exposed to 100mM BzATP
in the presence/absence of A-SMase inhibitors. (B) Time course analysis of Yo-PRO-1 uptake in astrocytes from A-SMase wild type (þ/þ),
heterozygous (þ/ )o rK O(  / ) animals on 100mM BzATP exposure. (n¼2; **Po0.01 versus controls, ANOVA analysis, Dunnett’s method).
Figure 7 Model for P2X7R-induced signalling pathway involved in MP shedding and large pore opening in glial cells. On BzATP stimulation,
P2X7R activates p38 MAPK cascade through src kinase-mediated phosphorylation. In turn, P-p38 triggers different pathways, among which PM
pore formation (a), and mobilisation of A-SMase from luminal lysosomal compartment to PM outer leaﬂet (b) where the enzyme alters
membrane structure/ﬂuidity leading to PM blebbing and shedding. Differently from exosomes, shed MPs carry IL-1b cytokine, present A-SMase
and high levels of PS on their membrane outer leaﬂet and are 100–1000nm in size.
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changes in lipid storage and cholesterol trafﬁcking conse-
quent to A-SMase absence need further investigation, our
results rule out the possibility that block of MP release may
be caused by secondary non-speciﬁc problems of KO animals.
Up to 90% of SM is localised in the outer membrane leaﬂet
(Koval and Pagano, 1991), thus, it is fully accessible for the
enzyme shifted into the membrane. However, if SM is hydro-
lyzed extracellularly, ceramide has to redistribute within the
lipid bilayer, as clustering of ceramide into the inner leaﬂet,
due to the spontaneous negative curvature of the lipid, can
facilitate formation of PM protrusions (Goni and Alonso,
2006). Previous studies have shown that A-SMase may have
an extracellular action, as showed by the enzyme secretion
and the capability to move onto the cell surface in response to
such stimuli such as CD95 or Pseudomonas aeruginosa
infection (Grassme ´ et al, 2001). Enrichment of A-SMase in
MPs suggests that formation of membrane protrusions occurs
from speciﬁc PM domains, the so-called lipid rafts, where
accumulation of ceramide by local translocation of A-SMase
can promote the enlargement of these domains (Garcia-
Marcos et al, 2006) and facilitate membrane blebbing. In
such domains, cytoskeleton/membrane proteins, possibly
directly interacting with the P2X7R- and P2X7R-dependent
signalling components, could be recruited. Interestingly, a
domain analogous to the TNFR1 death domain has been
described in the C-terminus of the P2X7R, which could target
the receptor to lipid rafts.
P2X7-induced signalling pathway of MP shedding
This study provides novel insights into the signalling path-
way downstream of P2X7Rs, which regulates MP shedding in
glial cells. Our data support a model (Figure 7) in which,
among the multiple intracellular signals coupled to P2X7R,
p38 MAPK cascade is required for the shedding process;
indeed we found that P38 becomes promptly phosphorylated
on P2X7R activation, also in the absence of extracellular Na
þ
and Ca
2þ and in high extracellular K
þ, indicating that P2X7R
regulates p38 activation by a metabotropic pathway indepen-
dent of the channel function of the receptor. Inhibition of p38
phosphorylation by PP2 indicates the involvement of an
src-protein tyrosine kinase as a link between P2X7R and p38,
as also suggested by Suzuki et al (2004). The Src homology 3
(SH3) domains of these soluble kinases may well interact
with the SH3-binding motif present in the C-terminus of the
P2X7R (Denlinger et al, 2001). P-p38 induces translocation of
endogenous A-SMase into the outer membrane leaﬂet and
stimulates the enzyme activity, thus, inducing SM breakdown
and ceramide generation. Although how P-p38 can induce
A-SMase translocation and activation remains to be comple-
tely elucidated, our data clearly indicate that P-p38 acts
upstream of A-SMase activity.
P2X7-induced vesicle shedding and large pore opening
So far controversial results have been published concerning
P2X7-dependent p38 activation, opening of large membrane
pores and release of IL-1b. In THP-1 monocytes, p38 inhibi-
tion does not alter IL-1b release although it inhibits large pore
opening (Donnelly-Roberts et al, 2004). Inhibition of pore
formation by p38 blockers has also been reported in perito-
neal macrophages (Faria et al, 2005), whereas no effect has
been detected in peripheral macrophages (Da Cruz et al,
2006). Our data indicate that YO-PRO uptake is blocked by
agents that interfere with p38 cascade, downstream of P2X7R.
Recently, the large pore that opens on P2X7R activation has
been identiﬁed with pannexin-1, a membrane protein that
forms gap junctions when expressed in oocytes and epithelial
cells. Blockade of pannexin-1 abolishes caspase-1 processing
and IL-1b release, thus, indicating a role of pannexin-1 in
cytokine processing and secretion (Pelegrin and Surprenant,
2006, 2007). However, P2X7R-mediated, pannexin-1-depen-
dent dye uptake is unlikely responsible for caspase-1 activa-
tion and IL-1b processing, because dye uptake occurs in high
extracellular K
þ, when IL-1b release is abrogated (Pelegrin
and Surprenant, 2007). Our ﬁnding that A-SMase inhibitors
and genetic deﬁciency of A-SMase do not affect the ability of
the P2X7R to induce dye uptake, while strongly inhibiting the
cytokine release, further conﬁrms that pore opening is not
directly involved in IL-1b processing and release. Pore open-
ing and IL-1b release through MP shedding are, in fact, two
parallel events occurring downstream of P2X7R-dependent
p38 phosphorylation (Figure 7). Furthermore, although
P2X7R-dependent p38 phosphorylation (this study) and
blebbing do not require ion inﬂux through the receptor,
extracellular Ca
2þ is necessary for MP shedding
(MacKenzie et al, 2001; Bianco et al, 2005) and processing
of IL-1b, at least in some cell types as microglia and mono-
cytes (Brough et al, 2003; Gudipaty et al, 2003).
Imipramine, an old drug for inhibiting IL-1b release
in brain pathologies?
Other pathways besides MP shedding have been proposed to
mediate IL-1b release from monocytes/macrophages, includ-
ing exocytosis of secretory lysosomes and exosomes (Andrei
et al, 1999; Qu et al, 2007). Complete blockade of MP shedding
and IL-1b release from A-SMase KO astrocytes indicates that
release of MPs from PM represents the major mechanism
mediating secretion of the cytokine from glial cells.
Concerning the possible contribution of secretory lysosomes,
although it has been recently reported that IL-1b release is not
affected in macrophages isolated from mice carrying a mutated
Lyst gene, which have impaired lysosomal secretion (Brough
and Rothwell, 2007), our results do not allow to exclude the
contribution of these organelles to the cytokine release.
Consistent with the role of A-SMase in IL-1b secretion,
reduced levels of IL-1b have been reported in the brain of
A-SMase KO mice (Ng and Grifﬁn, 2006), although A-SMase
might not be necessary for the cytokine release outside the
nervous system (Grassme ´ et al, 2003). Under this respect it
might be tempting to speculate that the increased frequency of
infections observed both in A-SMase KO animals and in patient
affected with Niemann Pick type A and B diseases (Minai et al,
2000; Ikegami et al, 2003) might be related with the capability
of A-SMase to control cytokine release (Leventhal et al, 2001)
and consequently to regulate the immune responses. A-SMase
can, therefore, represent a new suitable target for the pharma-
cological treatment of pathologies, like multiple sclerosis (MS),
where IL-1b is implicated. Previous studies have described that
interference with the IL-1b-mediated inﬂammatory pathway
has a positive outcome in experimental autoimmune encepha-
lomyelitis (EAE) mice, a well-characterised model of MS
(Martin and Near, 1995; Wiemann et al, 1998; Furlan et al,
1999). Interestingly, the antidepressant drug imipramine, be-
sides improving depression symptoms (Pollak et al, 2002), was
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study, showing that imipramine, which is also a A-SMase
inhibitor, blocks release of IL-1b vesicles by hampering
A-SMase mediated MP shedding, deﬁnes the possible
molecular mechanisms underlying previous observations in
EAE-mice. Given that the efﬁcacy of current therapies for MS is
rather limited and is mainly aimed at slowing the progression
of the disease, the present identiﬁcation of imipramine, a
widely used tricyclic antidepressant, as a potent blocker of
IL-1b release could be of great relevance as a starting point to
identify more efﬁcacious drugs for the pharmacological treat-
ment for this pathology.
Materials and methods
Cell cultures and cell stimulation
Glial cells were obtained and maintained as described previously
(Calegari et al, 1999; Bianco et al, 2005). Human glioblastoma cell
line ADF was obtained from PG Natali (Istituto Regina Elena, Rome,
Italy) and cultured as described in Supplementary data. For
induction of PM-derived MPs see Supplementary data.
Vesicle isolation by differential centrifugation
Isolation of vesicle populations by differential centrifugation was
implemented from a previous paper (Marzesco et al, 2005), as
described in Supplementary data.
Quantiﬁcation of PM-derived MPs
Spectrophotometric quantiﬁcation of FM1-43-labelled MPs was
carried out in KRH devoid of BSA as described previously
(Supplementary data; Bianco et al, 2005).
Fluorescence microscopy of vesicles
P2, P3 and P4 pellets were obtained from BzATP-stimulated,
conﬂuent astrocytes or N9 cells by differential centrifugation and
stained as described in Supplementary data.
FACS analysis
P2, P3 and P4 pellets were obtained from BzATP-stimulated,
conﬂuent astrocytes (24 10
6 cells) or conﬂuent N9 cells (42 10
6
cells) by differential centrifugation and analysed as described in
Supplementary data by a FacsCalibur ﬂow cytometer (Becton
Dickinson). Analysis of surface A-SMase in intact cells by FACS
was carried out as described in Supplementary data.
A-SMase cell surface labelling and immunoprecipitation
Analysis of A-SMase cell surface exposure was carried out by
biotinylation and subsequent western blotting as described in
Supplementary data.
Electron microscopy of vesicles
P2, P3 and P4 pellets from BzATP-stimulated astrocytes or N9 cells
were ﬁxed with 4% paraformaldehyde in PBS for 12h at 41C and
processed for negative staining electron microscopy (Supplemen-
tary data).
Measurement of A-SMase activity
A-SMase activity was determined as described previously (Falcone
et al, 2004).
IL-1b ELISA
Cells were primed for 6h with 100ng/ml LPS. A mouse IL-1b ELISA
kit (Pierce Endogen, Italy) was used to quantify the presence of
IL-1b in the supernatant of astrocytes and microglia cells stimulated
with 100mM BzATP.
Chemicals and antibodies
For chemicals see Supplementary data. Rabbit Ab versus ribophorin
(1:2000) were kindly provided by Dr Kreibich (New York University,
New York, NY, USA). Mouse Ab versus Na
þ/K
þ ATPase (1:5000)
and rabbit Ab versus GLAST N-epitope (1:150) were provided by
Dr Pietrini, University of Milan, Italy. Rabbit Ab versus P-p38 MAPK
(1:400) was from Cell Signalling Technology (USA) and goat Ab
versus IL-1b (1:1000) was from R&D (USA). The anti-A-SMase
rabbit polyclonal Ab (1:500) was generated in the lab and described
in Perrotta et al (2007). Example of speciﬁcity of this Ab in western
blotting is shown in Supplementary Figure 4. Mouse monoclonal
anti-HSP70 Ab (BRM-22 clone, 1:1000) and mouse monoclonal
GFAP Ab (G-A-5 clone, 1:1000) were from Sigma. Goat polyclonal
anti-CD63/LAMP3 Ab (clone M-13, 1:50) was from Santa Cruz
Biotech. Rabbit polyclonal anti-Cathepsin B Ab (1:200) was from
Chemicon. Rabbit polyclonal anti-CB1 Ab (1:500) was kindly
provided by Dr Mackie, University of Washington, Seattle, USA.
Statistical analysis
All data are presented as means±s.e. from the indicated number of
experiments. Statistical signiﬁcance was evaluated using either
Student’s t-test or one-way ANOVA analysis of variance. The
differences were considered to be signiﬁcant if Po0.05 and are
indicated by an asterisk; those at Po0.01 are indicated by double
asterisks.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
Acknowledgements
We thank A Colombo and G Biella (University of Milano, Italy) for
help in some experiments; Dr F Di Virgilio (University of Ferrara,
Italy) for the P2X7-deﬁcient N9 microglial clone; Dr M Canossa
(University of Bologna, Italy) and Dr L Galli-Resta (CNR Institute of
Neuroscience, Pisa, Italy) for helpful comments and discussion.
This work was supported by FISM (2007/R35) to CV, CARIPLO
20060948 and EU-Synapse Integrated Project (LSHM-CT-2005-
019055) to MM and AIRC (Italian Cancer Association) to EC. CP is
recipient of an AIRC fellowship. Research in EHS lab was supported
by NIH grant R01HD28607. Grant S Paolo 2500.1964.
References
Andrei C, Dazzi C, Lotti L, Torrisi MR, Chimini G, Rubartelli A
(1999) The secretory route of the leaderless protein interleukin
1beta involves exocytosis of endolysosome-related vesicles. Mol
Biol Cell 10: 1463–1475
Bianco F, Pravettoni E, Colombo A, Schenk U, Moller T, Matteoli M,
Verderio C (2005) Astrocyte-derived ATP induces vesicle
shedding and IL-1 beta release from microglia. J Immunol 174:
7268–7277
Brough D, Le Feuvre RA, Wheeler RD, Solovyova N, Hilﬁker S,
Rothwell NJ, Verkhratsky A (2003) Ca2+ stores and Ca2+ entry
differentially contribute to the release of IL-1 beta and IL-1 alpha
from murine macrophages. J Immunol 170: 3029–3036
Brough D, Rothwell NJ (2007) Caspase-1-dependent processing of
pro-interleukin-1beta is cytosolic and precedes cell death. J Cell
Sci 120: 772–781
Calegari F, Coco S, Taverna E, Bassetti M, Verderio C, Corradi N,
Matteoli M, Rosa P (1999) A regulated secretory pathway in
cultured hippocampal astrocytes. J Biol Chem 274: 22539–22547
Chang CP, Zhao J, Wiedmer T, Sims PJ (1993) Contribution of platelet
microparticle formation and granule secretion to the transmembrane
migration of phosphatidylserine. JB i o lC h e m268: 7171–7178
Coleman ML, Sahai EA, Yeo M, Bosch M, Dewar A, Olson MF (2001)
Membrane blebbing during apoptosis results from caspase-
mediated activation of ROCK I. Nat Cell Biol 3: 339–345
da Cruz CM, Ventura AL, Schachter J, Costa-Junior HM, da Silva
Souza HA, Gomes FR, Coutinho-Silva R, Ojcius DM, Persechini
PM (2006) Activation of ERK1/2 by extracellular nucleotides in
macrophages is mediated by multiple P2 receptors independently
of P2X7-associated pore or channel formation. Br J Pharmacol
147: 324–334
A-SMase induces vesicles release from glial cells
F Bianco et al
The EMBO Journal VOL 28 | NO 8 | 2009 &2009 European Molecular Biology Organization 1052Denlinger LC, Fisette PL, Sommer JA, Watters JJ, Prabhu U, Dubyak
GR, Proctor RA, Bertics PJ (2001) Cutting edge: the nucleotide
receptor P2X7 contains multiple protein- and lipid-interaction
motifs including a potential binding site for bacterial lipopoly-
saccharide. J Immunol 167: 1871–1876
Donnelly-Roberts DL, Namovic MT, Faltynek CR, Jarvis MF
(2004) Mitogen-activated protein kinase and caspase signaling
pathways are required for P2X7 receptor (P2X7R)-induced pore
formation in human THP-1 cells. J Pharmacol Exp Ther 308:
1053–1061
Duan S, Neary JT (2006) P2X(7) receptors: properties and relevance
to CNS function. Glia 54: 738–746
Falcone S, Perrotta C, De Palma C, Pisconti A, Sciorati C,
Capobianco A, Rovere-Querini P, Manfredi AA, Clementi E
(2004) Activation of acid sphingomyelinase and its inhibition
by the nitric oxide/cyclic guanosine 30,50-monophosphate path-
way: key events in Escherichia coli-elicited apoptosis of dendritic
cells. J Immunol 173: 4452–4463
Faria RX, Defarias FP, Alves LA (2005) Are second messengers
crucial for opening the pore associated with P2X7 receptor? Am J
Physiol Cell Physiol 288: 260–271
Faure ´ J, Lachenal G, Court M, Hirrlinger J, Chatellard-Causse C, Blot
B, Grange J, Schoehn G, Goldberg Y, Boyer V, Kirchhoff F, Raposo
G, Garin J, Sadoul R (2006) Exosomes are released by cultured
cortical neurones. Mol Cell Neurosci 4: 642–648
Ferrari D, Chiozzi P, Falzoni S, Dal Susino M, Collo G, Buell G, Di
Virgilio F (1997) ATP-mediated cytotoxicity in microglial cells.
Neuropharmacology 9: 1295–1301
Furlan R, Martino G, Galbiati F, Poliani PL, Smiroldo S, Bergami A,
Desina G, Comi G, Flavell R, Su MS, Adorini L (1999) Caspase-1
regulates the inﬂammatory process leading to autoimmune
demyelination. J Immunol 163: 2403–2409
Garcia-Marcos M, Pochet S, Marino A, Dehaye JP (2006) P2X7 and
phospholipid signalling: the search of the ‘‘missing link’’ in
epithelial cells. Cell Signal 18: 2098–2104
Goni FM, Alonso A (2006) Biophysics of sphingolipids I. Membrane
properties of sphingosine, ceramides and other simple sphingo-
lipids. Biochim Biophys Acta 1758: 1902–1921
Grassme ´ H, Jekle A, Riehle A, Schwarz H, Berger J, Sandhoff K,
Kolesnick R, Gulbins E (2001) CD95 signaling via ceramide-rich
membrane rafts. J Biol Chem 276: 20589–20596
Grassme ´ H, Jendrossek V, Riehle A, von Ku ¨rthy G, Berger J,
Schwarz H, Weller M, Kolesnick R, Gulbins E (2003) Host defense
against Pseudomonas aeruginosa requires ceramide-rich mem-
brane rafts. Nat Med 9: 322–330
Gudipaty L, Munetz J, Verhoef PA, Dubyak GR (2003) Essential role
for Ca2+ in regulation of IL-1beta secretion by P2X7 nucleotide
receptor in monocytes, macrophages, and HEK-293 cells. Am J
Physiol Cell Physiol 285: 286–299
Gulbins E, Jekle A, Ferlinz K, Grassme ´ H, Lang F (2000) Physiology
of apoptosis. Am J Physiol Renal Physiol 4: 605–615
Gulbins E (2003) Regulation of death receptor signaling and apop-
tosis by ceramide. Pharmacol Res 47: 393–399
Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ (1999)
Activated platelets release two types of membrane vesicles:
microvesicles by surface shedding and exosomes derived from
exocytosis of multivesicular bodies and alpha-granules. Blood 11:
3791–3799
Ikegami M, Dhami R, Schuchman EH (2003) Alveolar lipoprotei-
nosis in an acid sphingomyelinase-deﬁcient mouse model of
Niemann-Pick disease. Am J Physiol Lung Cell Mol Physiol 284:
518–525
Koval M, Pagano RE (1991) Intracellular transport and metabolism
of sphingomyelin. Biochim Biophys Acta 1082: 113–125
Lepine S, Le Stunff H, Lakatos B, Sulpice JC, Giraud F (2006) ATP-
induced apoptosis of thymocytes is mediated by activation of P2
X 7 receptor and involves de novo ceramide synthesis and
mitochondria. Biochim Biophys Acta 1761: 73–82
Leventhal AR, Chen W, Tall AR, Tabas I (2001) Acid sphingomye-
linase-deﬁcient macrophages have defective cholesterol trafﬁck-
ing and efﬂux. J Biol Chem 276: 44976–44983
Locovei S, Scemes E, Qiu F, Spray DC, Dahl G (2007) Pannexin1 is
part of the pore forming unit of the P2X(7) receptor death
complex. FEBS Lett 581: 483–488
MacKenzie A, Wilson HL, Kiss-Toth E, Dower SK, North RA,
Surprenant A (2001) Rapid secretion of interleukin-1beta by
microvesicle shedding. Immunity 15: 825–835
Marchesini N, Hannun YA (2004) Acid and neutral sphingomyeli-
nases: roles and mechanisms of regulation. Biochem Cell Biol 82:
27–44
Martin D, Near SL (1995) Protective effect of the interleukin-1
receptor antagonist (IL-1ra) on experimental allergic encephalo-
myelitis in rats. J Neuroimmunol 61: 241–245
Marty V, Me ´dina C, Combe C, Parnet P, Ame ´de ´e T (2005) ATP
binding cassette transporter ABC1 is required for the release of
interleukin-1beta by P2X7-stimulated and lipopolysaccharide-
primed mouse Schwann cells. Glia 49: 511–519
Marzesco AM, Janich P, Wilsch-Brauninger M, Dubreuil V,
Langenfeld K, Corbeil D, Huttner WB (2005) Release of extra-
cellular membrane particles carrying the stem cell marker pro-
minin-1 (CD133) from neural progenitors and other epithelial
cells. J Cell Sci 118: 2849–2858
Minai OA, Sullivan EJ, Stoller JK (2000) Pulmonary involvement in
Niemann-Pick disease: case report and literature review. Respir
Med 12: 1241–1251
Morelli A, Chiozzi P, Chiesa A, Ferrari D, Sanz JM, Falzoni S, Pinton
P, Rizzuto R, Olson MF, Di Virgilio F (2003) Extracellular ATP
causes ROCK I-dependent bleb formation in P2X7-transfected
HEK293 cells. Mol Biol Cell 14: 2655–2664
Morelli AE, Larregina AT, Shufesky WJ, Sullivan ML, Stolz DB,
Papworth GD, Zahorchak AF, Logar AJ, Wang Z, Watkins SC,
Falo Jr LD, Thomson AW (2004) Endocytosis, intracellular sort-
ing, and processing of exosomes by dendritic cells. Blood 104:
3257–3266
Nedergaard M, Ransom B, Goldman SA (2003) New roles for
astrocytes: redeﬁning the functional architecture of the brain.
Trends Neurosci 10: 523–530
Neufeld EB, Cooney AM, Pitha J, Dawidowicz EA, Dwyer NK,
Pentchev PG, Blanchette-Mackie EJ (1996) Intracellular trafﬁck-
ing of cholesterol monitored with a cyclodextrin. J Biol Chem 271:
21604–21613
Ng CG, Grifﬁn DE (2006) Acid sphingomyelinase deﬁciency in-
creases susceptibility to fatal alphavirus encephalomyelitis.
J Virol 80: 10989–10999
Nurminen TA, Holopainen JM, Zhao H, Kinnunen PK (2002)
Observation of topical catalysis by sphingomyelinase coupled to
microspheres. J Am Chem Soc 124: 12129–12134
Pelegrin P, Surprenant A (2006) Pannexin-1 mediates large pore
formation and interleukin-1beta release by the ATP-gated P2X7
receptor. EMBO J 25: 5071–5082
Pelegrin P, Surprenant A (2007) Pannexin-1 couples to maitotoxin-
and nigericin-induced interleukin-1beta release through a dye
uptake-independent pathway. J Biol Chem 282: 2386–2394
Perrotta C, Bizzozero L, Falcone S, Rovere-Querini P, Prinetti A,
Schuchman EH, Sonnino S, Manfredi AA, Clementi E (2007)
Nitric oxide boosts chemoimmunotherapy via inhibition of acid
sphingomyelinase in a mouse model of melanoma. Cancer Res 67:
7559–7564
Pollak Y, Orion E, Goshen I, Ovadia H, Yirmiya R (2002)
Experimental autoimmune encephalomyelitis-associated beha-
vioral syndrome as a model of ‘depression due to multiple
sclerosis’. Brain Behav Immun 16: 533–543
Potolicchio I, Carven GJ, Xu X, Stipp C, Riese RJ, Stern LJ,
Santambrogio L (2005) Proteomic analysis of microglia-derived
exosomes: metabolic role of the aminopeptidase CD13 in neuro-
peptide catabolism. J Immunol 4: 2237–2243
Qu Y, Franchi L, Nunez G, Dubyak GR (2007) Nonclassical
IL-1 beta secretion stimulated by P2X7 receptors is
dependent on inﬂammasome activation and correlated
with exosome release in murine macrophages. J Immunol 179:
1913–1925
Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A,
Ratajczak MZ (2006) Membrane-derived microvesicles: impor-
tant and underappreciated mediators of cell-to-cell communica-
tion. Leukemia 20: 1487–1495
Sanz JM, Di Virgilio F (2000) Kinetics and mechanism of ATP-
dependent IL-1 beta release from microglial cells. J Immunol 164:
4893–4898
Schiera G, Proia P, Alberti C, Mineo M, Savettieri G, Di Liegro I
(2007) Neurons produce FGF2 and VEGF and secrete them at
least in part by shedding extracellular vesicles. J Cell Mol Med 6:
1384–1394
Simons K, Ikonen E (1997) Functional rafts in cell membranes.
Nature 387: 569–572
A-SMase induces vesicles release from glial cells
F Bianco et al
&2009 European Molecular Biology Organization The EMBO Journal VOL 28 | NO 8 | 2009 1053Simpson RJ, Jensen SS, Lim JW (2008) Proteomic proﬁling of
exosomes: current perspectives. Proteomics 19: 4083–4099
Slotte JP, Hedstrom G, Rannstrom S, Ekman S (1989) Effects of
sphingomyelin degradation on cell cholesterol oxidizability and
steady-state distribution between the cell surface and the cell
interior. Biochim Biophys Acta 985: 90–96
Smalheiser NR (2007) Exosomal transfer of proteins and RNAs at
synapses in the nervous system. Biol Direct 2: 35
Suzuki T, Hide I, Ido K, Kohsaka S, Inoue K, Nakata Y (2004)
Production and release of neuroprotective tumor necrosis factor
by P2X7 receptor-activated microglia. J Neurosci 24: 1–7
Taylor AR, Robinson MB, Gifondorwa DJ, Tytell M, Milligan CE
(2007) Regulation of heat shock protein 70 release in astrocytes:
role of signaling kinases. Dev Neurobiol 13: 1815–1829
Tepper AD, Ruurs P, Wiedmer T, Sims PJ, Borst J, van Blitterswijk
WJ (2000) Sphingomyelin hydrolysis to ceramide during the
execution phase of apoptosis results from phospholipid scram-
bling and alters cell-surface morphology. J Cell Biol 150: 155–164
The ´ry C, Boussac M, Ve ´ron P, Ricciardi-Castagnoli P, Raposo G,
Garin J, Amigorena S (2001) Proteomic analysis of dendritic cell-
derived exosomes: a secreted subcellular compartment distinct
from apoptotic vesicles. J Immunol 166: 7309–7318
Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F,
Schwille P, Brugger B, Simons M (2008) Ceramide triggers
budding of exosome vesicles into multivesicular endosomes.
Science 319: 1244–1247
Van Blitterswijk WJ, De Veer G, Krol JH, Emmelot P (1982)
Comparative lipid analysis of puriﬁed plasma membranes and
shed extracellular membrane vesicles from normal murine thy-
mocytes and leukemic GRSL cells. Biochim Biophys Acta 688:
495–504
Verhoef PA, Estacion M, Schilling W, Dubyak GR (2003) P2X7
receptor-dependent blebbing and the activation of Rho-effector
kinases, caspases, and IL-1 beta release. J Immunol 170:
5728–5738
Wiemann B, Van GY, Danilenko DM, Yan Q, Matheson C,
Munyakazi L, Ogenstad S, Starnes CO (1998) Combined treat-
ment of acute EAE in Lewis rats with TNF-binding protein and
interleukin-1 receptor antagonist. Exp Neurol 149: 455–463
The EMBO Journal is published by Nature
Publishing Group on behalf of European
Molecular Biology Organization. This article is licensed
under a Creative Commons Attribution-Noncommercial-
NoDerivativeWorks3.0Licence.[http://creativecommons.
org/licenses/by-nc-nd/3.0]
A-SMase induces vesicles release from glial cells
F Bianco et al
The EMBO Journal VOL 28 | NO 8 | 2009 &2009 European Molecular Biology Organization 1054